Search research articles
Contact Us
Filters
Showing results (451-460 of 462) with videos related to
Page
of 47
Sort By:
Lancet (London, England)
|
September 25, 2021
Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial
Paul Little, Nick A Francis, Beth Stuart, et al.
The Lancet. Respiratory Medicine
|
July 14, 2024
Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial
Paul Little, Jane Vennik, Kate Rumsby, et al.
Health Technology Assessment (Winchester, England)
|
July 12, 2023
Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
Paul Little, Nick A Francis, Beth Stuart, et al.
Lancet (London, England)
|
August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Ly-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
October 24, 2025
12 month follow-up of a randomised open label trial of nasal sprays and a behavioural intervention for respiratory tract infections (RTIs) in primary care
Paul Little, Jane Louise Vennik, Kate Rumsby, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
BMJ Open
|
July 14, 2018
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC<sup>4</sup> E): the ALIC<sup>4</sup> E protocol
Emily Bongard, Alike W van der Velden, Johanna Cook, et al.
The Lancet. Infectious Diseases
|
September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
BMJ Open
|
August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Oghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Page
of 47
Search research articles
Search
Showing results (451-460 of 462) with videos related to
Sort By:
Page
of 47
Lancet (London, England)
|
September 25, 2021
Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial
Paul Little, Nick A Francis, Beth Stuart, et al.
The Lancet. Respiratory Medicine
|
July 14, 2024
Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial
Paul Little, Jane Vennik, Kate Rumsby, et al.
Health Technology Assessment (Winchester, England)
|
July 12, 2023
Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
Paul Little, Nick A Francis, Beth Stuart, et al.
Lancet (London, England)
|
August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Ly-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
October 24, 2025
12 month follow-up of a randomised open label trial of nasal sprays and a behavioural intervention for respiratory tract infections (RTIs) in primary care
Paul Little, Jane Louise Vennik, Kate Rumsby, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
BMJ Open
|
July 14, 2018
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC<sup>4</sup> E): the ALIC<sup>4</sup> E protocol
Emily Bongard, Alike W van der Velden, Johanna Cook, et al.
The Lancet. Infectious Diseases
|
September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
BMJ Open
|
August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Oghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Page
of 47